SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Clark James David | SVP, Cont & Chief Acct Officer | 2026-06-26 | Tax withholding | 454 | $41K |
| Compton-Phillips Amy | EVP, Chief Medical Officer | 2026-05-31 | Tax withholding | 7618 | $693K |
| Newman Brian | EVP, Chief Financial Officer | 2026-05-31 | Tax withholding | 2478 | $225K |
| AGUIRRE FERNANDO | Director | 2026-05-21 | D | 1563 | $146K |
| ROBBINS LARRY | Director | 2026-05-21 | Open-market sell | 370462 | $34.6M |
| AGUIRRE FERNANDO | Director | 2026-05-20 | D | 30437 | $2.9M |
| ROBBINS LARRY | Director | 2026-05-20 | Open-market sell | 797628 | $74.6M |
| ROBBINS LARRY | Director | 2026-05-20 | Open-market sell | 152691 | $14.5M |
| ROBBINS LARRY | Director | 2026-05-20 | Open-market sell | 66881 | $6.4M |
| ROBBINS LARRY | Director | 2026-05-20 | Open-market sell | 800 | $77K |
| ROBBINS LARRY | Director | 2026-05-19 | Open-market sell | 1983387 | $187.3M |
| ROBBINS LARRY | Director | 2026-05-19 | Open-market sell | 151 | $14K |
| AGUIRRE FERNANDO | Director | 2026-05-14 | Grant/award | 1563 | $152K |
| BROWN C DAVID II | Director | 2026-05-14 | Grant/award | 1544 | $150K |
| Balser Jeffrey R. | Director | 2026-05-14 | Grant/award | 2058 | $200K |
| KIRBY J SCOTT | Director | 2026-05-14 | Grant/award | 1447 | $141K |
| Norwalk Leslie V | Director | 2026-05-14 | Grant/award | 1447 | $141K |
| SANSONE GUY P | Director | 2026-05-14 | Grant/award | 1447 | $141K |
| Mandadi Tilak | EVP, Chief Exp & Tech Officer | 2026-05-08 | Open-market sell | 69551 | $6.2M |
| CAPOZZI HEIDI B | EVP and Chief People Officer | 2026-04-01 | Tax withholding | 1334 | $97K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Recurring premium deficiency reserves across multiple quarters and product lines confirm structural underpricing and claims deterioration as the dominant risk, compounded by a wave of newly disclosed regulatory, operational, and technology exposures. State legislative threats to PBM-pharmacy vertical integration, new guaranty fund assessment obligations, H-1B visa constraints on physician recruitment, and explicit AI/cybersecurity risk disclosures collectively broaden the risk profile across four distinct themes. Two easing items — exit from Public Exchange exposure and resolution of the $231M Penn Treaty guaranty liability — provide partial offset but do not materially change the worsening trajectory.
4 company-specific · 2 eased/removed · 4 common-mode
Company recorded $919M in premium deficiency reserves in 2025 (Q1 and Q2) versus $1.1B in Q3 2024, but now recurring across multiple quarters and product lines, signaling ongoing underpricing and claims deterioration.
The reserves we hold for expected claims in our Insured Health Care Benefits products are based on estimates that involve an extensive degree of judgment and are inherently variable. Any reserve…
New disclosure of state legislative activity prohibiting PBM-pharmacy affiliation. Material regulatory risk to core vertical integration strategy and business model.
We may face increased regulatory risks related to our vertical integration strategy. Our vertical integration strategy may lead to increased regulatory and public scrutiny as a result of consumer…
Added explicit disclosure of crisis management, disaster recovery, and insurance limitations. New acknowledgment that procedures may be ineffective and coverage may be insufficient.
Extreme events, or the threat of extreme events, could materially impact our businesses. The occurrence of natural disasters or extreme weather events, such as hurricanes, tropical storms, floods…
New disclosure of guaranty fund assessment risk under state insurance laws, a previously unmentioned financial obligation affecting operating results and cash flows.
If we fail to comply with applicable laws and regulations, many of which are highly complex, we could be subject to significant adverse regulatory actions, including monetary penalties, or suffer…
Removal of detailed Public Exchange competitive and pricing risk disclosure suggests company exited or materially de-emphasized this business line, reducing exposure to margin pressure and regulatory uncertainty.
We can provide no assurance that we will be able to compete successfully on Public Exchanges or that our pricing or other actions will result in the profitability of our Public Exchange products. To…
Removal of guaranty fund assessment risk disclosure. Prior year cited $231M Penn Treaty liability. Easing suggests resolved or immaterial going forward.
We are exposed to risks relating to the solvency of other insurers. We are subject to assessments under guaranty fund laws existing in all states for obligations of insolvent insurance companies…
New explicit disclosure of AI-related risks including reputational, cybersecurity, data privacy, legal, regulatory and operational exposure. Material escalation of technology risk profile.
Risks Related to Our Operations • Data governance failures, the failure or disruption of our information technology or infrastructure, a cyberattack or other information security incident can…
New disclosure of DTC pharmaceutical sales risk and Medicaid rate sufficiency risk. Both represent newly articulated competitive and pricing pressures affecting profitability.
Each of our segments operates in a highly competitive and evolving business environment; and operating income in the industries in which we compete may decline. Each of our segments, Health Care…
New disclosure of immigration policy risk affecting physician recruitment and retention, a material operational constraint for healthcare delivery.
Our Health Care Delivery businesses face unique risks. Our health care delivery businesses, which include health risk assessments and primary care services, including senior-focused value-based…
New disclosure of H-1B visa program changes as a material cost driver and talent constraint, escalating labor cost and availability risks beyond prior wage/leave legislation.
Our operating results may be adversely affected by changes in laws and policies governing employers and by union organizing activity. Congress and certain state legislatures continue to consider and…
CVS Health appointed Teresa Heitsenrether to its board of directors effective November 18, 2026. Heitsenrether is a senior executive from JPMorgan Chase with nearly forty years of financial services leadership experience, bringing expertise in data, analytics, and technology transformation to the company's board during a strategic transition period.
View raw filing on EDGAR →CVS Health issued a press release on August 5, 2026 announcing second quarter 2026 results for the three months ended June 30, 2026, disclosing total revenues of $106.1 billion (up 7.3% YoY), diluted EPS of $2.31, and adjusted EPS of $2.58, along with raised full-year 2026 guidance. This is a standard quarterly earnings release filed under Item 2.02 and attached as Exhibit 99.1.
View raw filing on EDGAR →